浙江时迈药业

Simaide Biopharma is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, focused on the discovery and development of innovative antibody-based therapeutics for cancer and autoimmune diseases. The company utilizes its proprietary D-Body, S-Body, and n-Body platforms to generate bispecific and fully human monoclonal antibodies with enhanced efficacy and safety profiles. Its lead candidate, SMD101, is a bispecific antibody targeting HER2 and CD3 currently in Phase 1/2 clinical trials for HER2-positive solid tumors. Simaide's pipeline also includes several other multi-specific candidates targeting EGFR, PD-L1, and Claudin 18.2, reflecting its commitment to advancing next-generation immunotherapy. By integrating advanced antibody engineering with deep biological insights, the company strives to deliver high-potency therapies to patients worldwide.